Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial

Medicine, Pembrolizumab, Cohort, Internal medicine, Interim analysis, Adverse effect, Clinical endpoint, Oncology, Population, Clinical trial, Surgery, Cancer, Immunotherapy